The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The supplements are made using only vegetarian-sourced ingredients
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Subscribe To Our Newsletter & Stay Updated
